Satoshi Yoda

5.1k total citations
27 papers, 1.1k citations indexed

About

Satoshi Yoda is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Satoshi Yoda has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Satoshi Yoda's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (6 papers). Satoshi Yoda is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (6 papers). Satoshi Yoda collaborates with scholars based in Japan, United States and France. Satoshi Yoda's co-authors include Kenzo Soejima, Katsuhiko Naoki, Hiroyuki Yasuda, Ibiayi Dagogo‐Jack, Aaron N. Hata, Hideki Terai, Takashi Sato, Shinnosuke Ikemura, Ryosuke Satomi and Sohei Nakayama and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Satoshi Yoda

26 papers receiving 1.1k citations

Peers

Countries citing papers authored by Satoshi Yoda

Since Specialization

Citations

This map shows the geographic impact of Satoshi Yoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Yoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Yoda more than expected).

Fields of papers citing papers by Satoshi Yoda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Yoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Yoda. The network helps show where Satoshi Yoda may publish in the future.

Co-authorship network of co-authors of Satoshi Yoda

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Yoda. A scholar is included among the top collaborators of Satoshi Yoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Yoda. Satoshi Yoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers 2025 ·Translational Oncology ·Kimberly J. Briggs, Kevin M. Cottrell, (unknown), (unknown), Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, (unknown), Satoshi Yoda, (unknown), Samuel R. Meier, Yi Yu, Teng Teng, Alan Huang, John P. Maxwell	6
2	Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors 2024 ·Cancer Research ·(unknown), André A. Mignault, Douglas A. Whittington, (unknown), (unknown), (unknown), Satoshi Yoda, Shangtao Liu, Minjie Zhang, Kevin M. Cottrell, Samuel R. Meier, (unknown), (unknown), (unknown), Yi Yu, (unknown), Adam Crystal, Teng Teng, Kimberly J. Briggs	0
3	Alginate-based 3D cancer cell culture for therapeutic response modeling 2021 ·STAR Protocols ·Farideh Davoudi, (unknown), Satoshi Yoda, (unknown), (unknown), (unknown), Ellen Murchie, Aaron N. Hata, Henning Willers, Cyril H. Benes	4
4	Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer 2020 ·Annals of Oncology ·W. Marston Linehan, Stephen V. Liu, Caroline E. McCoach, Viola W. Zhu, Aaron C. Tan, Satoshi Yoda, Jennifer Peterson, Andrew Do, Kylie Prutisto-Chang, Ibiayi Dagogo‐Jack, Lecia V. Sequist, Lori J. Wirth, Jochen K. Lennerz, Aaron N. Hata, Mari Mino–Kenudson, Valentina Nardi, S.-H.I. Ou, Daniel Shao-Weng Tan, Justin F. Gainor	161
5	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients 2019 ·Cancer Chemotherapy and Pharmacology ·Tetsuo Tani, Katsuhiko Naoki, Hiroyuki Yasuda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Hideki Terai, Shinnosuke Ikemura, Takashi Sato, Kenzo Soejima	1
6	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities 2018 ·Pharmacology & Therapeutics ·Satoshi Yoda, Ibiayi Dagogo‐Jack, Aaron N. Hata	50
7	Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC. 2018 ·Journal of Clinical Oncology ·(unknown), Beow Y. Yeap, Lorin A. Ferris, Satoshi Yoda, Ibiayi Dagogo‐Jack, Jochen K. Lennerz, Justin F. Gainor, Alice T. Shaw	2
8	MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant 2017 ·Journal of Thoracic Oncology ·W. Marston Linehan, Viola W. Zhu, Satoshi Yoda, B.Y. Yeap, Nicholas A. Jessop, (unknown), Ibiayi Dagogo‐Jack, Kyle Gowen, (unknown), Jeff Ross, Saima Ali, Virginia L. Miller, Justin F. Gainor, Aaron N. Hata, A. John Iafrate, (unknown), Alice T. Shaw	2
9	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer 2017 ·JCO Precision Oncology ·Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, W. Marston Linehan, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz, Lorin A. Ferris, Zofia Piotrowska, James C.H. Hardwick, Donghui Huang, Mari Mino–Kenudson, A. John Iafrate, Aaron N. Hata, Beow Y. Yeap, Alice T. Shaw	200
10	Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib. 2016 ·Journal of Clinical Oncology ·Justin F. Gainor, Luc Friboulet, Satoshi Yoda, (unknown), Anna F. Farago, Jennifer Logan, Katherine R. Schultz, Lecia V. Sequist, Jeffrey A. Engelman, Alice T. Shaw	13
11	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer 2015 ·Japanese Journal of Clinical Oncology ·Shinnosuke Ikemura, Katsuhiko Naoki, Hiroyuki Yasuda, Ichiro Kawada, Satoshi Yoda, Hideki Terai, Takashi Sato, Kota Ishioka, Daisuke Arai, Keiko Ohgino, Hirofumi Kamata, Jun Miyata, Hiroki Kabata, Tomoko Betsuyaku, Kenzo Soejima	6
12	Unexpected Massive Hemorrhage Following the Removal of a Pleural Drainage Tube 2015 ·Internal Medicine ·(unknown), Satoshi Yoda	2
13	Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer 2014 ·Lung Cancer ·Satoshi Yoda, Kenzo Soejima, Junko Hamamoto, Hiroyuki Yasuda, Sohei Nakayama, Ryosuke Satomi, Hideki Terai, Shinnosuke Ikemura, Takashi Sato, Katsuhiko Naoki, Tomoko Betsuyaku	38
14	Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC 2013 ·Molecular Cancer Research ·Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Sohei Nakayama, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shinnosuke Ikemura, Takashi Sato, Satoshi Yoda, Ryosuke Satomi, Katsuhiko Naoki, Tomoko Betsuyaku	174
15	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma 2013 ·Molecular Medicine Reports ·Junko Hamamoto, Kenzo Soejima, Satoshi Yoda, Katsuhiko Naoki, Sohei Nakayama, Ryosuke Satomi, Hideki Terai, Shinnosuke Ikemura, Takashi Sato, Hiroyuki Yasuda, Yuichiro Hayashi, Michiie Sakamoto, Toru Takebayashi, Tomoko Betsuyaku	54
16	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer 2013 ·Lung Cancer ·Keiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, Yuichiro Hayashi, Junko Hamamoto, Katsuhiko Naoki, Daisuke Arai, Kota Ishioka, Takashi Sato, Hideki Terai, Shinnosuke Ikemura, Satoshi Yoda, Tetsuo Tani, (unknown), Tomoko Betsuyaku	41
17	The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing 2011 ·International Journal of Clinical Oncology ·Katsuhiko Naoki, Kenzo Soejima, Hiroaki Okamoto, Junko Hamamoto, Naoya Hida, Ichiro Nakachi, Hiroyuki Yasuda, Sohei Nakayama, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Koshiro Watanabe	39
18	Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer 2010 ·Lung Cancer ·Hiroyuki Yasuda, Kenzo Soejima, Sohei Nakayama, Ichiro Kawada, Ichiro Nakachi, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Hideo Watanabe, Katsuhiko Naoki, Yuichiro Hayashi, Akitoshi Ishizaka	17
19	A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients 2010 ·Cancer Chemotherapy and Pharmacology ·Satoshi Yoda, Kenzo Soejima, Hiroyuki Yasuda, Katsuhiko Naoki, Ichiro Kawada, Hideo Watanabe, Ichiro Nakachi, Ryosuke Satomi, Sohei Nakayama, (unknown), Hideki Terai, Takashi Sato, (unknown), Koichiro Asano	4
20	Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells 2008 ·Cancer Cell International ·Hideo Watanabe, Kenzo Soejima, Hiroyuki Yasuda, Ichiro Kawada, Ichiro Nakachi, Satoshi Yoda, Katsuhiko Naoki, Akitoshi Ishizaka	119

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact